Neurocrine Biosciences (NBIX) R&D In Process (2019 - 2020)
Historic R&D In Process for Neurocrine Biosciences (NBIX) over the last 3 years, with Q2 2021 value amounting to $5.0 million.
- Neurocrine Biosciences' R&D In Process fell 8913.04% to $5.0 million in Q2 2021 from the same period last year, while for Sep 2021 it was $169.5 million, marking a year-over-year decrease of 1553.38%. This contributed to the annual value of $154.3 million for FY2019, which is 314783.16% up from last year.
- Latest data reveals that Neurocrine Biosciences reported R&D In Process of $5.0 million as of Q2 2021, which was down 8913.04% from $118.5 million recorded in Q3 2020.
- In the past 5 years, Neurocrine Biosciences' R&D In Process ranged from a high of $118.5 million in Q3 2020 and a low of $5.0 million during Q2 2019
- For the 3-year period, Neurocrine Biosciences' R&D In Process averaged around $54.0 million, with its median value being $41.1 million (2019).
- In the last 5 years, Neurocrine Biosciences' R&D In Process surged by 82000.0% in 2020 and then tumbled by 8913.04% in 2021.
- Quarter analysis of 3 years shows Neurocrine Biosciences' R&D In Process stood at $36.2 million in 2019, then skyrocketed by 227.6% to $118.5 million in 2020, then plummeted by 95.78% to $5.0 million in 2021.
- Its R&D In Process was $5.0 million in Q2 2021, compared to $118.5 million in Q3 2020 and $46.0 million in Q2 2020.